Introduction
============

Prediabetes, also termed intermediate hyperglycaemia or non-diabetic hyperglycaemia, is a high risk metabolic state for diabetes, defined by glycaemic variables that are higher than normal but lower than the thresholds for diabetes.[@ref1] [@ref2] [@ref3] The prevalence of prediabetes is increasing worldwide. Reports estimate that more than 470 million people will have prediabetes by 2030.[@ref4] According to an expert panel of the American Diabetes Association, up to 70% of individuals with prediabetes will eventually develop diabetes.[@ref5] Our previous meta-analysis, which included 53 prospective cohort studies with more than 1.6 million participants, showed that compared with normoglycaemia, prediabetes was associated with a higher risk of atherosclerotic cardiovascular disease and all cause mortality after adjusting for multiple risk factors. The risk was increased even in people with prediabetes defined according to the criteria of the American Diabetes Association, which recommended a cut-off value of 5.6-6.9 mmol/L (100-125 mg/dL) for fasting plasma glucose to define impaired fasting glucose.[@ref6] The studies included in the previous meta-analysis were from the general population, so the health risk for prediabetes in patients with established atherosclerotic cardiovascular disease was not established. In recent years, many studies exploring the associations between prediabetes and the risk of cardiovascular disease and mortality have been published.[@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] On their own, most of the studies had limited power to draw solid conclusions, however, and their results have been debated. A recent contentious report in *Science* defined prediabetes as a "dubious diagnosis" because of the inconsistent association of prediabetes with cardiovascular disease and mortality.[@ref15] This opinion reflects the controversy around the term prediabetes, and international consensus is urgently needed.

Given these inconsistencies, we performed an updated meta-analysis to analyse the available data on the prognostic value of prediabetes in individuals with and without baseline atherosclerotic cardiovascular disease. Two key questions were explored: is prediabetes associated with an increased risk of all cause mortality and cardiovascular disease in the general population and in patients with a history of atherosclerotic cardiovascular disease; and are different definitions of prediabetes related to different prognoses?

Methods
=======

Search strategy and selection criteria
--------------------------------------

We performed the search in accordance with the recommendations of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.[@ref16] Electronic databases (PubMed, Embase, and Google Scholar) were searched for studies with a combined MeSH heading and text search strategy, with multiple terms associated with "blood glucose" and "cardiovascular disease" or "mortality." The first round search was conducted up to 30 June 2019, a second round search was updated on 9 December 2019, and a third round search was updated on 25 April 2020, during the revision process (see supplementary file 1 for the detailed method used to search PubMed). The strategies for the other databases were similar but adapted where necessary. Reference lists were manually checked to identify other potential studies.

Studies were included for analysis if they met these criteria: prospective cohort studies or post hoc analysis of clinical trials of adult individuals (aged ≥18), from the general population or from patients with atherosclerotic cardiovascular disease; blood glucose or glycated haemoglobin (HbA~1c~), and other cardiovascular risk factors, were evaluated at baseline; and adjusted relative risks, odds ratios, or hazard ratios (with 95% confidence intervals) were reported for all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke associated with prediabetes in comparison with normoglycaemia.

Prediabetes was defined as any or all of the following: impaired fasting glucose according to the definition of the American Diabetes Association (IFG-ADA)[@ref17] or the World Health Organization (IFG-WHO);[@ref18] impaired glucose tolerance[@ref18]; or raised HbA~1c~ according to the criteria of the American Diabetes Association (HbA~1c~-ADA)[@ref17] or the International Expert Committee (HbA~1c~-IEC).[@ref19] Normoglycaemia was defined according to the different guidelines ([table 1](#tbl1){ref-type="table"}).

###### 

Definitions of normoglycaemia and prediabetes according to different guidelines

                                         Normal glycaemia                 Prediabetes
  -------------------------------------- -------------------------------- ---------------------------------------------
  ADA FPG based definition[@ref17]       FPG \<5.6 mmol/L (\<100 mg/dL)   IFG-ADA: FPG 5.6-6.9 mmol/L (100-125 mg/dL)
  WHO FPG based definition[@ref18]       FPG \<6.1 mmol/L (\<110 mg/dL)   IFG-WHO: FPG 6.1-6.9 mmol/L (110-125 mg/dL)
  OGTT 2hPG based definition[@ref18]     2hPG \<7.8 mmol/L (140 mg/dL)    IGT: 2hPG 7.8-11.1 mmol/L (140-199 mg/dL)
  ADA HbA~1c~ based definition[@ref17]   HbA~1c~ \<39 mmol/mol (5.7%)     HbA1c 39-46 mmol/mol (5.7-6.4%)
  IEC HbA~1c~ based definition[@ref19]   HbA~1c~ \<42 mmol/mol (6.0%)     HbA1c 42-46 mmol/mol (6.0-6.4%)

2hPG=two hour postload plasma glucose; ADA=American Diabetes Association; FPG=fasting plasma glucose; HbA~1c~= glycated haemoglobin; IGT=impaired glucose tolerance; IEC=International Expert Committee; IFG=impaired fasting glucose; IFG-ADA=impaired fasting glucose according to the definition of the American Diabetes Association; IFG-WHO=impaired fasting glucose according to the definition of the World Health Organization; OGTT=oral glucose tolerance test.

Studies were excluded if: they were retrospective studies or case-control studies; enrolment was not from the general population or from patients with atherosclerotic cardiovascular disease; the risk of associated events was unadjusted; and the length of follow-up was less than a year. If multiple articles were derived from the same cohort and reported the same associated outcome, only the latest published report was included for analysis.

Data extraction and quality assessment
--------------------------------------

Two investigators (XC and YZ) independently conducted the literature searches and reviewed the full articles of potentially suitable studies. Quality assessment of the studies was based on the Newcastle-Ottawa quality assessment scale for observational studies,[@ref20] where a study is judged based on selection (four items, one point each), comparability (one item, up to two points), and exposure/outcome (three items, one point each), up to a maximum score of nine points. The quality of the studies was graded as poor (fewer than four points), fair (four to six points), and good (seven or more points).[@ref21] We also evaluated whether the studies had been adequately adjusted for potential confounders, that is, if they included at least five of six risk factors: sex; age; smoking; blood pressure, hypertension, or antihypertensive treatment; body mass index or other measures of overweight or obesity; and hypercholesterolaemia or serum concentrations of cholesterol.[@ref22] [@ref23]

Statistical analysis
--------------------

Primary outcomes were the risk of all cause mortality and composite cardiovascular events in the general population and in patients with atherosclerotic cardiovascular disease, respectively. Secondary outcomes were the risk of coronary heart disease and stroke in individuals with prediabetes compared with normoglycaemia. Data for outcomes adjusted for the highest number of variables were used for the meta-analysis. We combined the log relative risks or log hazard ratios and corresponding standard errors by the inverse variance approach. Where the odds ratios (ORs) were presented, data were converted to relative risks (RRs) for the meta-analysis (RR=OR/(\[1−pRef\]+\[pRef×OR\]), where pRef is the prevalence of the outcome in the reference group (normoglycaemia group).[@ref24] We used I^2^ statistics to test for heterogeneity. An I^2^ value of more than 50% was considered to indicate significant heterogeneity. Even when no statistically significant heterogeneity was seen, however, a random effects model was used as the primary approach to combine results across studies rather than the fixed effects model, owing to underlying methodological heterogeneity (eg, baseline characteristics of the participants, length of follow-up, and adjustment for confounders).

We calculated the absolute risk difference for all cause mortality and cardiovascular outcomes associated with prediabetes by multiplying the assumed comparator risk of each outcome of interest by the estimated RR−1, according to the recommendation of the Cochrane guidelines.[@ref25] We used the median risks of outcomes in individuals with normoglycaemia across studies as the assumed comparator risks. Absolute risk differences were expressed as events per 10 000 person years.

Subgroup analyses of primary outcomes were conducted according to sex (men *v* women), ethnicity (Asian *v* non-Asian), age (average \<60 *v* ≥60), sample size (\<5000 *v* ≥5000 participants), length of follow-up (\<10 years *v* ≥10 years), and study quality (adequate adjustment *v* inadequate adjustment). We also conducted sensitivity analyses where the use of random effects models was changed to fixed effects models for the meta-analysis or the relative risks were recalculated by omitting one study at a time. Publication bias was evaluated by inspecting funnel plots for the outcomes, and further tested with Begg's test and Egger's test.

Meta-regression analysis was used to determine the effect of the definition of prediabetes, ethnicity, sex, participants' age, length of duration, and number of adjusted confounders on the outcomes if the data were reported in more than 10 studies, according to the Cochrane guidelines.[@ref26] The regression coefficient was used to describe how the outcomes changed with the explanatory variable (the potential effect modifier). To assess whether the different ranges of fasting plasma glucose concentrations in impaired fasting glucose had heterogeneity for the prognosis, we reviewed studies with data for prognosis for fasting plasma glucose concentrations of 5.6-6.05 mmol/L (100-109 mg/dL) and 6.1-6.9 mmol/L (110-125 mg/dL), compared with those with fasting plasma glucose concentrations of less than 5.6 mmol/L; the pooled results were then compared for heterogeneity.

Analyses were performed with RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) and Stata 15.0 (StataCorp, College Station, TX). All P values were two tailed, and statistical significance was set at P=0.05.

Patient and public involvement
------------------------------

Most of the authors have been actively involved in the prevention of cardiometabolic disease and maintain strong community links for primary and secondary prevention of cardiovascular disease. The concerns about the association between health outcomes and prediabetes from the patient and public inspired the author team to perform the study. Because this study was a meta-analysis, patient recruitment or use of patient data was not required. Therefore, we did not involve patients and the public in setting the research question, in the outcome measures, in the design, or the implementation of the study. We also did not ask patients for advice on interpretation or writing up of results. Where possible, the results of this study will be disseminated to the patient community or individual patients through the investigators.

Results
=======

Studies retrieved and characteristics
-------------------------------------

Our initial search returned 31 662 articles. After screening titles and abstracts, 307 articles qualified for a full review ([fig 1](#f1){ref-type="fig"}), and 129 studies, involving 10 069 955 individuals, were included in the analysis. Ninety seven studies (9 972 629 participants with a median follow-up time of 9.8 years, supplementary file 2) and 32 studies (97 326 participants with a median follow-up time of 3.2 years, supplementary file 3) reported an association of prediabetes with the primary outcomes in the general population and in patients with atherosclerotic cardiovascular disease, respectively.
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The key characteristics of the studies included in the meta-analysis are presented in supplementary files 4 and 5. Of the 129 studies included, 50 were from Europe, 47 from Asia, 25 from North America (United States and Canada), two from South America (Brazil), three from Oceania (Australia), and one from Africa (Mauritius). One study included patients from Europe and Asia. Based on adjusted confounders, 91 studies (67 from the general population and 24 from patients with atherosclerotic cardiovascular disease) met our criteria for adequate adjustment, while 38 studies (30 from the general population and eight from patients with atherosclerotic cardiovascular disease) did not adequately adjust for potential confounders (supplementary files 6 and 7). According to the Newcastle-Ottawa quality assessment scale, 15 studies (11 from the general population and four from patients with atherosclerotic cardiovascular disease) were graded as having fair quality; all other studies were graded as having good quality. Details of the quality assessment are presented in supplementary files 8 and 9.

All cause mortality and cardiovascular disease associated with prediabetes in the general population
----------------------------------------------------------------------------------------------------

In the general population, prediabetes was associated with an increased risk of all cause mortality (relative risk 1.13, 95% confidence interval 1.10 to 1.17), composite cardiovascular disease (1.15, 1.11 to 1.18), coronary heart disease (1.16, 1.11 to 1.21), and stroke (1.14, 1.08 to 1.20; [fig 2](#f2){ref-type="fig"}). Significant heterogeneity was seen for the risk of all outcomes (all I^2^ \>50%, P\<0.05) except for coronary heart disease (I^2^=23.3%, P=0.24), for the different definitions of prediabetes.

![Association between prediabetes and the risk of all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke in the general population. HbA~1c~-ADA=raised glycated haemoglobin according to the definition of the American Diabetes Association; HbA~1c~-IEC=raised glycated haemoglobin according to the recommendation of the International Expert Committee; IFG-ADA=impaired fasting glucose according to the definition of the American Diabetes Association; IFG-WHO=impaired fasting glucose according to the definition of the World Health Organization; IGT=impaired glucose tolerance](caix056552.f2){#f2}

Compared with normoglycaemia, the risk of all cause mortality was significantly increased when prediabetes was defined as IFG-ADA (relative risk 1.07, 95% CI 1.03 to 1.12), IFG-WHO (1.13, 1.05 to 1.20), impaired glucose tolerance (1.25, 1.17 to 1.32), HbA~1c~-IEC (1.21, 1.06 to 1.38), or combined IFG-WHO and impaired glucose tolerance (1.17, 1.13 to 1.20), but not in studies with other definitions of prediabetes ([fig 2](#f2){ref-type="fig"}). The risk of cardiovascular disease was increased when prediabetes was defined as IFG-ADA (relative risk 1.09, 95% confidence interval 1.03 to 1.15), IFG-WHO (1.20, 1.09 to 1.34), impaired glucose tolerance (1.23, 1.13 to 1.32), HbA~1c~-ADA (1.17, 1.03 to 1.33), or combined IFG-ADA and impaired glucose tolerance (1.21, 1.03 to 1.42), but not in studies with other definitions of prediabetes ([fig 2](#f2){ref-type="fig"}). [Figure 2](#f2){ref-type="fig"} also shows the associations of different definitions of prediabetes and the risk of coronary heart disease and stroke. The relative risks of all outcomes in individual studies are presented in supplementary files 10-13. We found no evidence of publication bias for all outcomes associated with prediabetes identified by visual inspection of the funnel plot (supplementary file 14) or by Begg's test and Egger's test (all P\>0.10).

When cardiovascular outcomes or mortality associated with fasting plasma glucose concentrations of 5.6-6.05 mmol/L versus concentrations less than 5.6 mmol/L, or fasting plasma glucose concentrations of 6.1-6.9 mmol/L versus concentrations less than 5.6 mmol/L were reported in the same study, data were pooled to explore whether a step increase in the risk of all cause mortality or composite cardiovascular disease existed in the fasting plasma glucose range in the IFG-ADA definition. Compared with a fasting plasma glucose concentration of less than 5.6 mmol/L, concentrations of 5.6-6.05 mmol/L were associated with only a mildly increased risk of coronary heart disease (relative risk 1.05, 95% confidence interval 1.01 to 1.10) but not with other outcomes. Fasting plasma glucose concentrations of 6.1-6.9 mmol/L were associated with an increased risk of all cause mortality (1.26, 1.16 to 1.36), coronary heart disease (1.12, 1.05 to 1.19), and stroke (1.18, 1.05 to 1.32). Significant heterogeneity was seen for the risk of all cause mortality (I^2^=92.3%, P\<0.001) and stroke (I^2^=76.5%, P=0.04), but not for composite cardiovascular disease or coronary heart disease, when fasting plasma glucose concentrations of 6.1-6.9 mmol/L were compared with concentrations of 5.6-6.05mmol/L ([fig 3](#f3){ref-type="fig"}).
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The absolute risks of all cause mortality and cardiovascular outcomes in individuals with normoglycaemia across studies from the general population are presented in supplementary file 15. Compared with normoglycaemia, the absolute risk difference in prediabetes for all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke was 7.36 (95% confidence interval 9.59 to 12.51), 8.75 (6.41 to 10.49), 6.59 (4.53 to 8.65), and 3.68 (2.10 to 5.26) per 10 000 person years, respectively. The absolute risk differences for men and women separately are presented in supplementary file 15.

All cause mortality and cardiac outcomes associated with prediabetes in patients with atherosclerotic cardiovascular disease
----------------------------------------------------------------------------------------------------------------------------

In patients with atherosclerotic cardiovascular disease, prediabetes was associated with an increased risk of all cause mortality (relative risk 1.36, 95% confidence interval 1.21 to 1.54), composite cardiovascular disease (1.37, 1.23 to 1.53), and coronary heart disease (1.15, 1.02 to 1.29), but no difference was seen for the risk of stroke (1.05, 0.81 to 1.36; [fig 4](#f4){ref-type="fig"} and supplementary files 16-19). We found no significant heterogeneity for the risk of all outcomes for the different definitions of prediabetes (all I^2^ \<50%, P\>0.10). Furthermore, the IFG-ADA definition was associated with an increased risk of all cause mortality (relative risk 1.60, 95% confidence interval 1.15 to 2.22) and composite cardiovascular disease comorbidity (1.33, 1.02 to 1.75) in patients with established atherosclerotic cardiovascular disease. No evidence of publication bias for all outcomes associated with prediabetes was identified by visual inspection of the funnel plot (supplementary file 20) or by Begg's test and Egger's test (all P\>0.10).

![Association between prediabetes and the risk of all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke in patients with atherosclerotic cardiovascular disease. HbA~1c~-ADA=raised glycated haemoglobin according to the definition of the American Diabetes Association; HbA~1c~-IEC=raised glycated haemoglobin according to the recommendation of the International Expert Committee; IFG-ADA=impaired fasting glucose according to the definition of the American Diabetes Association; IFG-WHO=impaired fasting glucose according to the definition of the World Health Organization; IGT=impaired glucose tolerance](caix056552.f4){#f4}

The absolute risks of all cause mortality and cardiovascular outcomes in individuals with normoglycaemia across studies from patients with atherosclerotic cardiovascular disease are presented in supplementary file 21. Compared with normoglycaemia, the absolute risk difference in prediabetes for all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke was 66.19 (95% confidence interval 38.60 to 99.25), 189.77 (117.97 to 271.84), 40.62 (5.42 to 78.53), and 8.54 (−32.43 to 61.45) per 10 000 person years, respectively. We did not report the absolute risk difference associated with men and women separately because of the limited number of studies available.

Subgroup analyses, meta-regression analyses, and sensitivity analyses
---------------------------------------------------------------------

The predefined subgroup analyses showed that in the general population, prediabetes was associated with an increased risk of all cause mortality (relative risk range 1.08-1.17), composite cardiovascular disease (1.10-1.22), coronary heart disease (1.09-1.22), and stroke (1.07-1.35) in most subgroup comparisons. We found no significant heterogeneity in most of the subgroup comparisons ([table 2](#tbl2){ref-type="table"}).

###### 

Subgroup analyses of the association between prediabetes and outcomes in general population

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                                                            All cause mortality                         Composite cardiovascular disease        Coronary heart disease                         Stroke                                                                                                        
  ------------------------------------------------------------------- --------------------- --------------------- ---------------------------------- ---- ------------------------ --------------------- -------- --------------------- ---- --------------------- --------------------- -- ---- --------------------- -------
  **Ethnicity**                                                                                                                                                                                                                                                                                                        

  Asian                                                               44                    1.14 (1.09 to 1.19)   0.96                                    54                       1.12 (1.07 to 1.17)   0.29                           37   1.09 (1.05 to 1.12)   0.01                     22   1.11 (1.06 to 1.17)   0.23

  Non-Asian                                                           43                    1.14 (1.09 to 1.18)                                      56   1.16 (1.11 to 1.22)                            28       1.20 (1.12 to 1.29)        22                    1.19 (1.08 to 1.33)                                 

  **Sex**                                                                                                                                                                                                                                                                                                              

  Men                                                                 30                    1.13 (1.08 to 1.19)   0.60                                    33                       1.15 (1.09 to 1.22)   0.72                           23   1.11 (1.05 to 1.17)   0.11                     12   1.10 (1.05 to 1.15)   0.70

  Women                                                               25                    1.16 (1.09 to 1.23)                                      28   1.17 (1.08 to 1.27)                            23       1.19 (1.11 to 1.29)        10                    1.07 (0.93 to 1.22)                                 

  **Participant's average age**                                                                                                                                                                                                                                                                                        

  \<60                                                                56                    1.16 (1.12 to 1.20)   0.02                                    69                       1.15 (1.11 to 1.20)   0.15                           48   1.19 (1.13 to 1.25)   0.22                     31   1.13 (1.07 to 1.20)   0.27

  ≥60                                                                 29                    1.08 (1.03 to 1.14)                                      33   1.10 (1.05 to 1.16)                            13       1.11 (1.02 to 1.22)        13                    1.23 (1.07 to 1.42)                                 

  **Sample**                                                                                                                                                                                                                                                                                                           

  \<5000                                                              34                    1.15 (1.08 to 1.23)   0.70                                    45                       1.22 (1.15 to 1.30)   0.02                           33   1.16 (1.10 to 1.22)   0.78                     23   1.23 (1.09 to 1.40)   0.17

  ≥5000                                                               53                    1.13 (1.10 to 1.17)                                      65   1.12 (1.08 to 1.16)                            32       1.17 (1.11 to 1.24)        21                    1.12 (1.06 to 1.19)                                 

  **Length of follow-up (years)**                                                                                                                                                                                                                                                                                      

  \<10                                                                52                    1.11 (1.07 to 1.15)   0.09\                                   59                       1.10 (1.06 to 1.14)   0.009                          28   1.09 (1.05 to 1.13)   0.007                    16   1.11 (1.06 to 1.16)   0.15

  ≥10                                                                 35                    1.17 (1.12 to 1.23)                                      51   1.20 (1.14 to 1.27)                            37       1.19 (1.13 to 1.27)        28                    1.20 (1.09 to 1.32)                                 

  **Possibility of enrolling patients with cardiovascular disease**                                                                                                                                                                                                                                                    

  None                                                                28                    1.08 (1.04 to 1.13)   0.03                                    52                       1.14 (1.09 to 1.19)   0.88                           52   1.18 (1.12 to 1.24)   0.03                     38   1.15 (1.09 to 1.22)   0.99

  Might enrolled                                                      59                    1.16 (1.12 to 1.20)                                      58   1.15 (1.09 to 1.21)                            13       1.08 (1.02 to 1.15)        6                     1.15 (0.92 to 1.45)                                 

  **Adjustment of confounders**                                                                                                                                                                                                                                                                                        

  Adequate†                                                           72                    1.15 (1.11 to 1.19)   0.11                                    84                       1.14 (1.10 to 1.18)   0.44                           47   1.15 (1.09 to 1.21)   0.13\                    31   1.11 (1.05 to 1.17)   0.003

  Not adequate                                                        15                    1.08 (1.00 to 1.17)                                      26   1.18 (1.09 to 1.27)                            18       1.22 (1.15 to 1.30)        12                    1.35 (1.20 to 1.51)                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For heterogeneity in subgroups.

Adequate adjustment denotes adjustment of at least five of six confounders: sex; age; hypertension, blood pressure, or antihypertensive treatment; body mass index or other measure of overweight or obesity; cholesterol; and smoking.

In patients with atherosclerotic cardiovascular disease, the risk of all cause mortality associated with prediabetes was higher in Asian (relative risk 1.66, 95% confidence interval 1.37 to 2.01) than in non-Asian patients (1.22, 1.07 to 1.40; P=0.01 for heterogeneity). The risk of composite cardiovascular disease was higher in women with prediabetes (2.26, 1.27 to 4.04) than in men with prediabetes (1.16, 0.54 to 2.47; P=0.02 for heterogeneity). No significant heterogeneity was seen in the other subgroup comparisons for all outcomes (all P\>0.05; [table 3](#tbl3){ref-type="table"}).

###### 

Subgroup analyses of association between prediabetes and outcomes in patients with atherosclerotic cardiovascular disease

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                          All cause mortality                         Composite cardiovascular disease        Coronary heart disease                         Stroke                                                                                                        
  --------------------------------- --------------------- --------------------- ---------------------------------- ---- ------------------------ --------------------- -------- --------------------- ---- --------------------- --------------------- -- ---- --------------------- ------
  **Ethnicity**                                                                                                                                                                                                                                                                      

  Asian                             9                     1.66 (1.37 to 2.01)   0.01                                    11                       1.42 (1.21 to 1.67)   0.47                           4    1.35 (1.08 to 1.70)   0.14                     2    1.12 (0.74 to 1.70)   0.97

  Non-Asian                         15                    1.22 (1.07 to 1.40)                                      20   1.32 (1.14 to 1.51)                            9        1.11 (0.97 to 1.27)        3                     1.11 (0.71 to 1.71)                                 

  **Sex**                                                                                                                                                                                                                                                                            

  Men                               1                     1.57 (0.83 to 2.95)   0.93                                    2                        1.16 (0.54 to 2.47)   0.02                           NA   ---                   ---\                     NA   ---                   ---

  Women                             1                     1.68 (0.45 to 6.29)                                      2    2.26 (1.27 to 4.04)                            NA       ---                        NA                    ---                                                 

  **Participant's average age**                                                                                                                                                                                                                                                      

  \<60                              5                     1.32 (1.16 to 1.49)   0.44                                    9                        1.29 (1.08 to 1.54)   0.43                           4    1.22 (1.02 to 1.47)   0.42                     3    1.03 (0.71 to 1.50)   0.52

  ≥60                               19                    1.44 (1.19 to 1.73)                                      22   1.42 (1.22 to 1.65)                            9        1.16 (1.00 to 1.36)        2                     1.24 (0.81 to 1.88)                                 

  **Sample**                                                                                                                                                                                                                                                                         

  \<5000                            20                    1.50 (1.26 to 1.78)   0.11                                    26                       1.40 (1.21 to 1.61)   0.19                           10   1.11 (0.97 to 1.26)   0.08                     4    1.08 (0.79 to 1.47)   0.99

  ≥5000                             4                     1.24 (1.05 to 1.45)                                      5    1.24 (1.12 to 1.38)                            3        1.38 (1.12 to 1.71)        1                     1.09 (0.51 to 2.33)                                 

  **Length of follow-up (years)**                                                                                                                                                                                                                                                    

  \<10                              21                    1.44 (1.25 to 1.66)   0.04                                    29                       1.40 (1.24 to 1.58)   0.21                           13   1.15 (1.02 to 1.29)   ---                      5    1.05 (0.81 to 1.36)   ---

  ≥10                               2                     1.20 (1.08 to 1.33)                                      2    1.07 (0.71 to 1.60)                            NA       ---                        NA                    ---                                                 

  **Adjustment of confounders**                                                                                                                                                                                                                                                      

  Adequate†                         17                    1.40 (1.23 to 1.59)   0.64                                    22                       1.27 (1.15 to 1.41)   0.21                           8    1.20 (1.06 to 1.36)   0.45                     4    0.97 (0.78 to 1.23)   0.18

  Not adequate                      7                     1.28 (0.90 to 1.81)                                      9    1.61 (1.12 to 2.32)                            5        1.07 (0.82 to 1.40)        1                     1.71 (0.77 to 3.78)                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA=not applicable.

For heterogeneity in subgroups.

Adequate adjustment denoted adjustment of at least five of six confounders: sex; age; hypertension, blood pressure, or antihypertensive treatment; body mass index or other measure of overweight or obesity; cholesterol; and smoking.

Meta-regression analysis showed that in the general population, impaired glucose tolerance carried a higher risk of all cause mortality (P=0.002) and stroke (P=0.043) compared with impaired fasting glucose. The prediabetes IFG-WHO definition also had a higher risk of stroke than the IFG-ADA definition (P=0.02, supplementary file 22). In patients with atherosclerotic cardiovascular disease, the risk of all cause mortality associated with prediabetes was also higher in Asian than in non-Asian patients (P=0.03), as reported in the subgroup analysis. No other significant associations in study characteristics and risk of endpoint events were seen (all P\>0.10, supplementary file 23).

The sensitivity analyses confirmed that the association between prediabetes and risk of endpoint events did not change with the use of random effects models or fixed effects models for the meta-analysis, or with recalculation of the relative risks by omitting one study at a time.

Discussion
==========

Principal findings
------------------

In this comprehensive meta-analysis with 129 studies involving more than 10 million participants, three major findings emerged. Firstly, compared with normoglycaemia, prediabetes was associated with an increased risk of all cause mortality and cardiovascular disease in the general population and in patients with atherosclerotic cardiovascular disease. Secondly, in the general population, impaired glucose tolerance carried a higher risk of all cause mortality, coronary heart disease, and stroke than impaired fasting glucose. Thirdly, the risk of all cause mortality associated with impaired fasting glucose was mainly attributed to fasting plasma glucose concentrations in the range 6.1-6.9 mmol/L.

Comparison with previous studies
--------------------------------

According to the current definition of the American Diabetes Association, the prevalence of prediabetes in adults is up to 36.2% in the United States[@ref27] and 35.7% in China.[@ref28] Despite discrepancies in definitions, the prevalence of prediabetes is clearly rising. The term prediabetes, however, has been much debated. One view is that recognition of this condition could help to boost efforts to reduce the future burden of diabetes and its complications.[@ref4] [@ref29] The counterargument is that describing people with an increased risk of type 2 diabetes as having prediabetes creates more problems than benefits in terms of prevention and treatment, resulting in unnecessary medical intervention and an unsustainable burden on healthcare systems.[@ref15] [@ref30] In 2016, our group reported that prediabetes, defined as impaired fasting glucose according to the definition of the American Diabetes Association or the World Health Organization, or impaired glucose tolerance, was associated with increased all cause mortality and cardiovascular disease in the general population.[@ref6] In this study, we updated our data and further supported our previous research, which showed that the risk of all cause mortality and cardiovascular disease was increased in people with prediabetes, even when defined according to the lower cut-off point of impaired fasting glucose proposed by the current definition of the American Diabetes Association.

Furthermore, our study showed new findings. Firstly, significant heterogeneity was found for the risk of all cause mortality and cardiovascular disease for different definitions of prediabetes in the general population. Individuals with impaired glucose tolerance were susceptible to a higher risk of all cause mortality than those with impaired fasting glucose. The increased risk was seen even when fasting plasma glucose concentrations were as low as 5.6-6.9 mmol/L, supported by a meta-analysis of individual participant data performed by the Emerging Risk Factors Collaboration, which showed that fasting plasma glucose concentrations exceeding 5.6 mmol/L were associated with increased mortality.[@ref31] We also found that the risk was mainly driven by fasting plasma glucose concentrations in the range 6.1-6.9 mmol/L. These results are important for future selection of those at high risk for prevention trials. Secondly, the inclusion of HbA~1c~ as a criterion for diabetes and prediabetes has led to concerns of its limited use for predicting future cardiovascular disease events.[@ref32] In this study, we found that the risk of composite cardiovascular events and coronary heart disease was increased in the general population with a HbA~1c~ concentration of 39-47 mmol/mol (5.7-6.4%). These results provide evidence for the inclusion of HbA~1c~ in defining prediabetes. HbA~1c~ is an easier method for screening than the oral glucose tolerance test, which is time consuming. Hence this information would help stratification to prioritise a screening programme. Thirdly, we found that prediabetes was also associated with an increased risk of mortality and cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease. These results suggest that managing prediabetes in patients with established atherosclerotic cardiovascular disease might also be an important goal to lower their future risk of recurrent cardiovascular disease and premature death.

Implications of the study and future research
---------------------------------------------

Considering the high prevalence of prediabetes, and the robust and significant association between prediabetes and health risk shown in our study, successful intervention in this large population could have a major effect on public health. Although prediabetes is commonly asymptomatic, it represents a window of opportunity to prevent progression to type 2 diabetes and its complications.[@ref33] Community mobilisation and lifestyle intervention for prediabetes can lead to a significant reduction in the incidence of diabetes.[@ref29] [@ref34] Follow-up studies from the Diabetes Prevention Programme have shown that lifestyle intervention can be cost effective in preventing diabetes, and that treatment with metformin can even be cost saving.[@ref35] The Let's Prevent Diabetes cluster randomised controlled trial showed that a relatively low resource, a pragmatic diabetes prevention programme, had modest benefits for biomedical, lifestyle, and psychosocial outcomes.[@ref36] Two systematic reviews and network meta-analyses also reported that lifestyle intervention in prediabetes is beneficial in reducing the risk of progression to type 2 diabetes.[@ref37] [@ref38] Furthermore, the 30 year results of the Da Qing Diabetes Prevention Outcome Study showed that lifestyle intervention in people with impaired glucose tolerance reduced the incidence of cardiovascular events and all cause mortality, providing strong justification for intervention for prediabetes.[@ref39]

Similarly, the NAVIGATOR (long term study of nateglinide and valsartan to prevent or delay type II diabetes mellitus and cardiovascular complications) trial showed that in individuals at high risk of cardiovascular disease with impaired glucose tolerance, baseline levels of daily ambulatory activity and change in ambulatory activity showed a graded inverse association with the subsequent risk of a cardiovascular event.[@ref40] Based on these results, guidelines from the European Society of Cardiology on diabetes, prediabetes, and cardiovascular disease recommended lifestyle changes as a key prevention aspect of type 2 diabetes and cardiovascular disease.[@ref41] Data on prevention of cardiovascular disease in people with impaired fasting glucose or raised HbA~1c~ concentrations are lacking. However, whether results from trials with impaired glucose tolerance will apply to individuals with other definitions of prediabetes is questionable. Thus intervention studies in prediabetes identified by fasting plasma glucose or HbA~1c~ concentrations are warranted.

In patients with atherosclerotic cardiovascular disease, the risk of all cause mortality associated with prediabetes was higher in Asian than in non-Asian patients. Although a chance finding cannot be excluded, previous studies have suggested plausible and interesting mechanisms. Firstly, compared with their Western counterparts, Asian individuals might have a different pattern for complications of diabetes.[@ref42] A meta-analysis of interventional randomised controlled trials showed that the risk of microvascular events and new or worsening nephropathy was significantly higher in Asian patients than in western patients.[@ref43] In our analysis, the risk of macrovascular disease (composite cardiovascular disease, coronary heart disease, and stroke) associated with prediabetes was similar in Asian and non-Asian patients. Therefore, the increased risk of all cause mortality might be attributed to microvascular events. This finding is further supported by previous studies which showed that Asian patients with prediabetes might progress more rapidly to clinical diabetes,[@ref44] and when they develop diabetes, microvascular complications develop more rapidly.[@ref45]

Secondly, differences in genetics, socioeconomic factors, and treatment approaches for atherosclerotic cardiovascular disease between Asia and other continents might also have a role in the influence of prediabetes on mortality in Asia.[@ref43] [@ref46] Based on these results, prediabetes management programmes, tailored to Asian patients with atherosclerotic cardiovascular disease, might be clinically important, and these programmes should be investigated in future studies. Thirdly, in patients with atherosclerotic cardiovascular disease, there might be a survival advantage associated with overweight or obesity (so-called obesity paradox).[@ref47] [@ref48] Phenotypic differences in people with impaired glucose regulation have been seen between ethnic groups. Asian populations develop impaired glucose regulation at lower levels of body mass index than European populations,[@ref49] and therefore they might not experience the obesity paradox similarly to their Western counterparts.

Strengths and limitations of the study
--------------------------------------

Our study has several strengths. Firstly, only prospective cohort studies or post hoc analysis of clinical trials with adjusted relative risks were included. Most of the studies included in the analysis were of high quality and adequately adjusted for confounders. This might mitigate the possibility of other cardiovascular risk factors influencing the association of prediabetes with the health risk observed. Secondly, the number of available studies and the sample size were large, which allowed us to perform multiple subgroup analyses and meta-regression analysis to explore the association in different definitions of prediabetes and the risk of mortality and cardiovascular disease. Similar risk across subgroups according to age, sex, and length of follow-up further strengthens our conclusion.

Some limitations of the study should be noted. Firstly, we had no access to individual participants' data and potential confounders could not be ruled out. Secondly, it is unclear whether the increased risk seen in our study was a result of prediabetes or the transition from prediabetes to diabetes during follow-up. Several studies have provided evidence that the increased risk associated with prediabetes is not, however, dependent on progression to diabetes. A Finnish study showed that an increased risk of cardiovascular disease associated with impaired glucose tolerance remained significant after excluding patients with impaired glucose tolerance who subsequently developed overt diabetes during follow-up analyses.[@ref50] Similarly, a nested case-control study from Japan showed that persistent prediabetes, defined by fasting plasma glucose concentrations of 5.6-6.9 mmol/L or HbA~1c~ 39-47 mmol/mol (5.7-6.4%), was associated with an increased risk of cardiovascular disease. Furthermore, in people with prediabetes before progression to overt diabetes, inverse linear associations were found between measures of glycaemia (HbA~1c~, fasting, and two hour postload glucose concentrations) and microvascular function, independent of cardiovascular risk factors.[@ref51] Thirdly, in most of the included studies, people with low blood glucose concentrations were not excluded. Some studies have shown that the association of fasting plasma glucose concentrations with cardiovascular disease has a J shaped curve.[@ref52] [@ref53] [@ref54] The inclusion of people with low blood glucose concentrations in the reference group would make the association of prediabetes and risk towards null. Fourthly, we did not find that the risk of stroke was associated with prediabetes in patients with baseline atherosclerotic cardiovascular disease. Most of the studies included patients with coronary heart disease, however, only one study included patients based on previous stroke. Therefore, whether prediabetes is associated with the recurrent risk of stroke is still unclear.

Conclusions
-----------

Prediabetes was associated with an increased risk of all cause mortality and cardiovascular disease in the general population and in patients with atherosclerotic cardiovascular disease. Screening and proper management of prediabetes might contribute to primary and secondary prevention of cardiovascular disease.

### What is already known on this topic

1.  Prediabetes is a common condition worldwide with a high prevalence

2.  A previous meta-analysis showed that prediabetes was associated with an increased risk of cardiovascular events in the general population, although this finding was controversial

3.  Reports on the association of prediabetes with prognosis in patients with a history of cardiovascular disease are inconsistent

### What this study adds

1.  Prediabetes was associated with an increased risk of cardiovascular disease and all cause mortality

2.  Different definitions of prediabetes were associated with a similar prognosis in patients with a history of cardiovascular disease

3.  Screening and proper management of prediabetes might contribute to primary and secondary prevention of cardiovascular disease
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